GlycaNova is focused on the development of its technology in the treatment of cancer and is currently conducting a pioneering, placebo-controlled clinical trial in which late-stage colorectal cancer patients are receiving GlycaNova’s LentinexHP in addition to chemotherapy. The commercialisation strategy for the product, subject to the results of the clinical trial, is expected to comprise an out-licensing agreement to a marketing partner either on a worldwide or territorial basis.
GlycaNova markets its consumer healthcare products, including Lentinex, Immuna and Ganodex, via a combination of distribution partners and direct sales. It is also developing products for animal health.
Please contact us with any enquiries in connection with potential distribution partnerships or licensing agreements.